Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Talsupram (Lu 5-005 or Lu 5-003^[1]) is a selective norepinephrine reuptake inhibitor (NRI) which was investigated as an antidepressant in the 1960s and 1970s but was never marketed.^[2]^[3]^[4] Along with talopram, it is structurally related to the selective serotonin reuptake inhibitor (SSRI) citalopram.^[5]

Talsupram

Norepinephrine TransporterNETBinding Affinity

Molecular FormulaC20H25NS

Molecular Weight311.5 g/mol

CAS No.21489-20-3

Cat. No.B1219376

Talsupram is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

21489-20-3

Post Buying Request

Basic information
1. Product Name: Talsupram
2. Synonyms: Talsupram;Lu 5-003;1,3-Dihydro-N,3,3-trimethyl-1-phenylbenzo[c]thiophene-1-propan-1-amine;Lu-5-005
3. CAS NO:21489-20-3
4. Molecular Formula: C20H25NS
5. Molecular Weight: 311.491
6. EINECS: N/A
7. Product Categories: N/A
8. Mol File: 21489-20-3.mol
Chemical Properties
1. Melting Point: N/A
2. Boiling Point: 427.6°Cat760mmHg
3. Flash Point: 212.4°C
4. Appearance: /
5. Density: 1.043g/cm³
6. Vapor Pressure: 1.62E-07mmHg at 25°C
7. Refractive Index: 1.569
8. Storage Temp.: N/A
9. Solubility: N/A
10. CAS DataBase Reference: Talsupram(CAS DataBase Reference)
11. NIST Chemistry Reference: Talsupram(21489-20-3)
12. EPA Substance Registry System: Talsupram(21489-20-3)
Safety Data
1. Hazard Codes: N/A
2. Statements: N/A
3. Safety Statements: N/A
4. WGK Germany:
5. RTECS:
6. HazardClass: N/A
7. PackingGroup: N/A
8. Hazardous Substances Data: 21489-20-3(Hazardous Substances Data)

21489-20-3 Suppliers

Recommended suppliers

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Chemlyte Solutions

Talsupram
Cas No: 21489-20-3
No Data
No Data
No Data
Hangzhou Lingrui Chemical Co.,Ltd.

Talsupram
Cas No: 21489-20-3
No Data
No Data
No Data
BOC Sciences

Talsupram
Cas No: 21489-20-3
No Data
No Data
No Data
Zibo Hangyu Biotechnology Development Co., Ltd

Benzo[c]thiophene-1-propanamine,1,3-dihydro-N,3,3-trimethyl-1-phenyl-
Cas No: 21489-20-3
No Data
No Data
No Data
indukern do brasil quimica ltda

21489-20-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 21489-20-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,1,4,8 and 9 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 21489-20:
(7*2)+(6*1)+(5*4)+(4*8)+(3*9)+(2*2)+(1*0)=103
103 % 10 = 3
So 21489-20-3 is a valid CAS Registry Number.

InChI:InChI=1/C20H25NS/c1-19(2)17-12-7-8-13-18(17)20(22-19,14-9-15-21-3)16-10-5-4-6-11-16/h4-8,10-13,21H,9,14-15H2,1-3H3

21489-20-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) – Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name	3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)-N-methylpropan-1-amine

1.2 Other means of identification

Product number	–
Other names	Talsupramum [INN-Latin]

1.3 Recommended use of the chemical and restrictions on use

Identified uses	For industry use only.
Uses advised against	no data available

1.4 Supplier’s details

1.5 Emergency phone number

Emergency phone number	–
Service hours	Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:21489-20-3 SDS

21489-20-3Upstream product

21489-20-3Downstream Products

Talsupram is a selective norepinephrine reuptake inhibitor (NRI). It was under research for the treatment of depression in 1960 and 1970 but it was never marketed. Talsupram presents a similar structure to [citalopram].

Overview

Talsupram is a chemical compound that has gained attention in pharmacological research, particularly in relation to its potential applications in neuroimaging and as a radioligand for the norepinephrine transporter. It is categorized as a norepinephrine transporter ligand, which indicates its role in modulating norepinephrine levels in the brain. Talsupram is structurally related to other compounds such as talopram, which have been studied for their antidepressant properties.

Source and Classification

Talsupram belongs to the class of compounds known as phenylindanamines, which are characterized by their phenyl and indane structures. The compound is synthesized for use in positron emission tomography (PET) imaging, particularly for studying the norepinephrine transporter in vivo. It has been evaluated alongside other radiolabeled compounds to assess its efficacy and binding properties in biological systems .

Synthesis Analysis

Methods

The synthesis of talsupram involves several steps, typically starting from commercially available precursors. A common method includes:

Starting Materials: The synthesis often begins with 3-amino-1,2-propanediol.
Reactions: Key reactions include nucleophilic aromatic substitutions and deprotection steps using various protecting groups.
Radiolabeling: For PET imaging purposes, talsupram can be radiolabeled with carbon-11 using methods that involve reacting tosylate precursors with fluoride ions in the presence of a phase transfer catalyst .

Technical Details

Molecular Structure Analysis

Structure

Talsupram’s molecular structure can be described as follows:

Chemical Formula: C_{17}H_{22}N_{2}
Molecular Weight: Approximately 270.37 g/mol
Structural Features: The compound features a phenyl group attached to an indanamine backbone, which is crucial for its activity as a norepinephrine transporter ligand.

Data

The compound’s three-dimensional structure can be analyzed using X-ray crystallography or computational modeling techniques to understand its interactions with biological targets better.

Chemical Reactions Analysis

Talsupram participates in various chemical reactions relevant to its synthesis and functionalization:

Nucleophilic Aromatic Substitution: This reaction is fundamental in forming the core structure of talsupram from simpler aromatic precursors.
Deprotection Reactions: Utilized to remove protecting groups after key synthetic steps, ensuring that the active sites are available for interaction with biological targets.
Radiolabeling Reactions: Involves fluorination processes that incorporate radioactive isotopes into the molecule for imaging purposes .

Mechanism of Action

Talsupram primarily functions as a norepinephrine transporter inhibitor. By binding to the norepinephrine transporter, it blocks the reuptake of norepinephrine into presynaptic neurons, thereby increasing the availability of this neurotransmitter in the synaptic cleft. This mechanism is similar to other antidepressants that target monoamine transporters and is essential for its potential therapeutic effects .

Physical and Chemical Properties Analysis

Physical Properties

Appearance: Typically presented as a solid or crystalline compound.
Solubility: Soluble in organic solvents such as dimethyl sulfoxide (DMSO) but may have limited solubility in water.

Chemical Properties

Relevant data regarding these properties can assist researchers in understanding how talsupram behaves under different experimental conditions.

Applications

Talsupram is primarily used in scientific research related to neuropharmacology and imaging studies:

Neuroimaging: Its application as a radioligand for PET scans allows researchers to visualize and quantify norepinephrine transporters in living subjects, contributing to studies on mood disorders and other neurological conditions.
Pharmacological Studies: Investigated for its potential antidepressant effects due to its mechanism of action on norepinephrine levels, providing insights into new treatment avenues for depression and anxiety disorders .

Introduction to Talsupram: Pharmacological Classification and Historical Context

Talsupram as a Selective Noradrenaline Reuptake Inhibitor (NRI)

Talsupram exerts its primary pharmacological effect through potent and selective inhibition of the norepinephrine transporter (NET). It demonstrates negligible affinity for the serotonin transporter (SERT) and dopamine transporter (DAT), distinguishing it from non-selective tricyclic antidepressants (TCAs). This selectivity was established through in vitro radioligand binding assays and in vivo neurotransmitter uptake studies:

In vitro affinity: Talsupram exhibits 20-30× greater potency for NET (K_i = 1.8 nM) compared to SERT (K_i = 48 nM) [1].
Functional activity: Preclinical studies confirmed talsupram’s ability to elevate synaptic norepinephrine concentrations by >70% without significant effects on serotonin or dopamine levels [3] [8].

Table 1: Neurotransmitter Transporter Affinity Profile of Talsupram

Transporter	Affinity (K_i, nM)	Selectivity Ratio (NET/SERT)
Norepinephrine (NET)	1.8 ± 0.4	1.0 (reference)
Serotonin (SERT)	48 ± 6	26.7
Dopamine (DAT)	>1000	>555

The compound’s specificity arises from its interaction with transmembrane domain 6 of NET, where its dimethylbenzothiophene moiety forms hydrophobic contacts critical for selective binding. This molecular precision enabled researchers to isolate noradrenergic effects from serotonergic modulation—a key objective in early monoamine pharmacology [3] [8].

Structural Analogues in the Tricyclic Antidepressant Family

Talsupram belongs to a structurally unique subclass of tricyclic compounds characterized by a bicyclic heteroaromatic system fused to a phenyl ring. Its core consists of a benzothiophene scaffold with a dimethyl substituent at the 3-position:

Table 2: Structural Evolution from Tricyclic Compounds to Talsupram and Analogues

Compound	Core Structure	Key Modifications	Pharmacological Class
Imipramine	Dibenzazepine	N-methylaminopropyl side chain	Non-selective TCA
Melitracen	9,10-Dihydroanthracene	Rigid tricyclic core with dimethylamine	NRI precursor
Talopram	Phthalane (isobenzofuran)	3,3-dimethyl substitution	NRI
Talsupram	Benzothiophene	3,3-dimethyl substitution; phenyl ring at C1	Selective NRI
Citalopram	Phthalane (isobenzofuran)	Fluorophenyl substitution; cyanophthalane	SSRI

Notable structural analogues include:

Talopram (Lu 3-010): An isobenzofuran analogue differing only in the heteroatom (oxygen vs. sulfur), retaining potent NET selectivity. Both compounds emerged from Lundbeck’s systematic modification of melitracen derivatives [4].
Citalopram: Synthesized through strategic structural optimization of talopram. Replacement of talsupram’s dimethylbenzothiophene with a cyanophthalane scaffold and fluorophenyl group shifted selectivity toward SERT inhibition (500× greater affinity for SERT over NET) [4] [7].
Prototype NRIs: Desipramine and nortriptyline represent classical tricyclic NRIs but lack talsupram’s selectivity due to significant muscarinic and histaminic receptor interactions. Their dibenzazepine cores contrast with talsupram’s planar benzothiophene system [8] [10].

The 3,3-dimethyl configuration in talsupram sterically hinders metabolism at the benzylic position, enhancing plasma stability compared to non-dimethylated analogues—a feature exploited in later antidepressant designs [4].

Historical Development Within Monoaminergic Drug Discovery

Talsupram’s development occurred during a transformative period in psychopharmacology defined by two key paradigms:

The Monoamine Hypothesis and TCA Evolution

The 1950s-1960s witnessed the serendipitous discovery of imipramine’s antidepressant properties, validating the monoamine depletion hypothesis of depression. First-generation TCAs like imipramine non-selectively inhibited both NET and SERT but caused significant anticholinergic and cardiovascular side effects. This drove efforts to develop subtype-selective reuptake inhibitors [3] [6]. Talsupram emerged from Lundbeck’s systematic exploration of melitracen derivatives. During melitracen synthesis, an unexpected phenylphthalene rearrangement produced talopram, which demonstrated selective norepinephrine reuptake inhibition. Talsupram was developed as its benzothiophene analogue shortly thereafter [4].

Bridging the TCA-SSRI Transition

Talsupram occupies a pivotal position in antidepressant history:

Clinical findings: Phase II trials revealed activating properties linked to suicidal ideation in some patients, mirroring concerns with other NRIs. This observation aligned with psychiatrist Paul Kielholz’s theory that noradrenergic activation posed greater suicide risk than serotonergic modulation [4].
Strategic pivot: Lundbeck redirected medicinal chemistry efforts toward serotonin selectivity. Klaus Bøgesø converted talopram into citalopram by introducing a cyano group and fluorophenyl substituent, achieving 400-fold SERT/NET selectivity [4] [7].
Legacy: Though talsupram was abandoned, its chemical architecture provided the template for citalopram—the first highly selective SSRI. This transition exemplified the shift from “accidental discovery” to rational drug design in psychiatric pharmacology [4] [7].

Table 3: Key Compounds in Lundbeck’s Antidepressant Development Pipeline (1960s-1980s)

Time Period	Lead Compound	Pharmacological Action	Clinical Outcome	Contribution to Drug Discovery
Early 1960s	Melitracen	Norepinephrine reuptake inhibition	Marketed (Europe)	Tricyclic NRI scaffold
1963-1965	Talopram (Lu 3-010)	Selective NRI	Abandoned in Phase III	Phenylphthalane core discovery
1967-1969	Talsupram (Lu 5-005)	Selective NRI	Abandoned in Phase II	Validated benzothiophene-based NRIs
1971-1975	Citalopram	Selective SERT inhibition	Marketed (1989)	First high-selectivity SSRI

Talsupram’s history illustrates the iterative nature of psychotropic drug development, where “failed” compounds provide critical structural insights for future breakthroughs [3] [4] [7].

Properties

CAS Number

21489-20-3

Product Name

Talsupram

IUPAC Name

3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)-N-methylpropan-1-amine

Molecular Formula

C20H25NS

Molecular Weight

311.5 g/mol

InChI

InChI=1S/C20H25NS/c1-19(2)17-12-7-8-13-18(17)20(22-19,14-9-15-21-3)16-10-5-4-6-11-16/h4-8,10-13,21H,9,14-15H2,1-3H3

InChI Key

FKHYYOUFMJBLAF-UHFFFAOYSA-N

SMILES

CC1(C2=CC=CC=C2C(S1)(CCCNC)C3=CC=CC=C3)C

Synonyms

1-(3-methylaminopropyl)-1-phenyl-3,3-dimethylthiophthalane hydrochloride
Lu 5-003
talsupram

Canonical SMILES

CC1(C2=CC=CC=C2C(S1)(CCCNC)C3=CC=CC=C3)C

talsupram

Talsupram structure

CAS No.: 21489-20-3

Chemical Name:: Talsupram

Synonyms: Lu-5-005;Lu 5-003;Talsupram;Benzo[c]thiophene-1-propanamine, 1,3-dihydro-N,3,3-trimethyl-1-phenyl-;1,3-Dihydro-N,3,3-trimethyl-1-phenylbenzo[c]thiophene-1-propan-1-amine

CBNumber:: CB21179835

Molecular Formula:: C20H25NS

Molecular Weight:: 311.48

MDL Number:: MFCD00865342

MOL File:: 21489-20-3.mol

Last updated:2022-12-21 16:56:50

Technical Parameters

Basic Identity

Product Name	Talsupram
CAS	21489-20-3
Synonyms	1-(3-methylaminopropyl)-1-phenyl-3,3-dimethylthiophthalane hydrochloride, Lu 5-003, talsupram
Molecular Formula	C20H25NS
Molecular Weight	311.5 g/mol

Structural Identifiers

SMILES	CC1(C2=CC=CC=C2C(S1)(CCCNC)C3=CC=CC=C3)C
InChI	InChI=1S/C20H25NS/c1-19(2)17-12-7-8-13-18(17)20(22-19,14-9-15-21-3)16-10-5-4-6-11-16/h4-8,10-13,21H,9,14-15H2,1-3H3
InChIKey	FKHYYOUFMJBLAF-UHFFFAOYSA-N

Commercial & Availability

Structure & Identifiers

Talsupram (CAS 21489-20-3): A High-Affinity, Selective Norepinephrine Reuptake Inhibitor (NRI) for Neuropharmacology Research

Talsupram (Lu 5-005) is a selective norepinephrine reuptake inhibitor (NRI) that was originally investigated as an antidepressant in the 1960s and 1970s but was never commercialized [1]. It is structurally related to the selective serotonin reuptake inhibitor (SSRI) citalopram, but features a key structural variation that redirects its pharmacological profile [2]. Talsupram is a high-affinity ligand for the norepinephrine transporter (NET) and is primarily used in research settings to selectively probe the role of noradrenergic signaling, including its application in neuropathic pain models [3].

Target engagementSelective norepinephrine reuptake inhibitor (NRI) for NET-specific signaling studies

Assay contextIn vitro and ex vivo pharmacology; not suited for CNS-penetration-dependent models

Research modelsReported application in rodent neuropathic pain models; peripheral target engagement

Why Norepinephrine Reuptake Inhibitors (NRIs) Like Talsupram Are Not Interchangeable

The class of norepinephrine reuptake inhibitors (NRIs) exhibits significant variation in both molecular structure and functional pharmacology, making generic substitution scientifically unsound. Talsupram’s benzothiophene core differentiates it from analogs like talopram (isobenzofuran core) and desipramine (tricyclic core), which in turn leads to distinct transporter binding affinities and selectivity profiles . Furthermore, in vivo functional outcomes, such as anti-hyperalgesic efficacy, have been shown to differ between talsupram and other monoamine reuptake inhibitors, underscoring that in-class potency does not directly translate to equivalent phenotypic effects [1].

Attribute

Talsupram (Target)

Typical Substitute Risk

Chemical scaffold

Benzothiophene core (S heteroatom)

Isobenzofuran analogs (e.g., talopram) may shift NET potency and selectivity

Transporter selectivity

>1000-fold NET-selective over SERT

Less selective NRIs (e.g., atomoxetine) may introduce serotonergic or dopaminergic modulation

CNS penetration

Poor blood-brain barrier penetration documented

CNS-penetrant NRIs (e.g., reboxetine) may not replicate peripheral-only response profile

Quantitative Evidence for Talsupram Differentiation vs. Closest Analogs

Superior Binding Affinity and Functional Inhibition of NET vs. Closest Structural and Pharmacological Analogs

Talsupram exhibits superior affinity and functional inhibition for the norepinephrine transporter (NET) compared to its closest structural analog, talopram, and other benchmark NRIs. Its IC50 for human NET inhibition is 0.79 nM, which is >3-fold more potent than talopram (IC50 = 2.9 nM) and >5-fold more potent than desipramine (Ki = 4 nM) . In rat brain tissue, talsupram’s Ki of 0.79 nM for NET is >5-fold lower than talopram’s Ki of 4.5 nM [1][2].

NET binding affinity

Cross-study comparable

IC50 = 0.79 nM (human NET)

Ki = 0.79 nM (rat NET)

Supports high-affinity NET target engagement in vitro

Reported >3-fold higher potency than talopram; >5-fold vs desipramine

Norepinephrine TransporterNETBinding AffinitySelectivityStructure-Activity Relationship

Enhanced NET Selectivity Profile Over SERT and DAT Compared to Other NRIs

Talsupram demonstrates a highly selective functional inhibition profile for NET over SERT and DAT. The IC50 for NET (0.79 nM) is >1000-fold lower than for SERT (850 nM) and >11,000-fold lower than for DAT (9300 nM) . This selectivity window is numerically larger than that observed for reboxetine in rat transporters (Ki NET = 1.1 nM, SERT = 129 nM, DAT >10,000 nM; ~117-fold over SERT) and substantially larger than that for atomoxetine (Ki NET = 5 nM, SERT = 77 nM, DAT = 1451 nM; ~15-fold over SERT) [1].

NET selectivity over SERT

Cross-study comparable

SERT/NET ratio ≈ 1076

SERT IC50 = 850 nM

Enables cleaner noradrenergic pathway isolation

Selectivity window >70-fold wider than atomoxetine based on reported data

SelectivityNorepinephrine TransporterSerotonin TransporterDopamine TransporterOff-target Activity

Differentiated Analgesic Efficacy in a Preclinical Model of Neuropathic Pain

In a rat model of neuropathic pain (partial sciatic nerve ligation), talsupram demonstrated significantly superior anti-hyperalgesic efficacy compared to vilazodone (a SERT inhibitor/5-HT1A partial agonist) and indatraline (a triple reuptake inhibitor) in the hot plate test, a supraspinal pain response assay [1][2]. Talsupram produced a higher percentage of maximal possible effect (MPE) at multiple doses, with the study concluding it was ‘significantly more effective’ than the other two drugs in this test [1].

Anti-hyperalgesic response

Head-to-head comparison

Higher %MPE vs. vilazodone, indatraline

Rat partial sciatic nerve ligation model

Reported superior pain-model endpoint response

Endpoint context: hot plate test at 2.5–10 mg/kg i.p.

Neuropathic PainAnalgesiaIn Vivo PharmacologyHot Plate TestAnti-hyperalgesia

Structural Basis for Pharmacological Differentiation: The Benzothiophene Core

Talsupram is structurally differentiated from its closest analog, talopram, by a single heteroatom substitution in its tricyclic core. Talsupram contains a benzothiophene ring (sulfur heteroatom), whereas talopram contains an isobenzofuran ring (oxygen heteroatom) [1]. This seemingly minor structural change results in a >3-fold increase in NET inhibitory potency (IC50 = 0.79 nM for talsupram vs. 2.9 nM for talopram) and a distinct selectivity profile . This represents a clear structure-activity relationship (SAR) where replacing oxygen with sulfur significantly enhances NET engagement.

Benzothiophene SAR

Class-level inference

S > O heteroatom substitution

May support scaffold-hopping design strategy

Reported ~3.7-fold potency increase over isobenzofuran analog

Medicinal ChemistryStructure-Activity RelationshipBenzothiopheneIsobenzofuranScaffold Hopping

CNS Penetration Liability: A Critical Limitation for In Vivo Brain Target Engagement

Despite its high in vitro potency and selectivity, talsupram exhibits poor blood-brain barrier (BBB) penetration. PET imaging studies in a rhesus monkey and biodistribution studies in rats demonstrated that radiolabeled [11C]talsupram ‘did not enter the CNS in adequate amounts to be used in PET imaging studies’ [1]. This was despite the compound’s high affinity and selectivity for NET in vitro, confirming that its BBB penetration is a significant translational limitation compared to CNS-penetrant NRIs like atomoxetine or reboxetine.

BBB penetration

Direct head-to-head comparison

Poor CNS exposure documented

PET imaging and biodistribution studies

Not suitable for CNS target-engagement models

Value limited to peripheral assays and ex vivo benchmarking

Blood-Brain BarrierCNS PenetrationPET ImagingBiodistributionTranslational Pharmacology

Defined Research and Industrial Applications for Talsupram Based on Its Specific Profile

Use as a High-Potency, Selective NET Inhibitor for In Vitro and Ex Vivo Pharmacology

Talsupram’s sub-nanomolar potency and high selectivity for NET over SERT and DAT make it an ideal tool compound for in vitro assays requiring clean noradrenergic target engagement. Applications include radioligand binding displacement studies, functional uptake assays in cells or synaptosomes, and ex vivo tissue studies where CNS penetration is not a requirement [1]. Its superior potency compared to talopram and greater selectivity compared to atomoxetine provide a higher degree of pharmacological precision [2].

A Validated Tool for Probing Noradrenergic Mechanisms in Rodent Models of Neuropathic Pain

Based on direct comparative in vivo evidence, talsupram is a validated research tool for studying the specific contribution of noradrenergic reuptake inhibition to analgesia in neuropathic pain models, such as the partial sciatic nerve ligation model in rats [1]. Its superior efficacy in the hot plate test over vilazodone and indatraline provides a specific, data-backed rationale for its selection in studies aimed at isolating the analgesic effects of NET inhibition from those of SERT or DAT modulation [1].

Chemical Probe and Scaffold for Medicinal Chemistry SAR Studies

The benzothiophene core of talsupram serves as a potent starting point for structure-activity relationship (SAR) studies aimed at developing novel NET inhibitors. Its >3-fold potency advantage over the oxygen-containing analog talopram provides a clear design hypothesis for optimizing NET affinity and selectivity [1]. Researchers can use talsupram as a benchmark in medicinal chemistry programs focused on scaffold hopping or improving drug-like properties for CNS penetration.

A Cautionary Tale in Translational Pharmacology for CNS Drug Development

The well-documented failure of talsupram to achieve adequate brain penetration despite exceptional in vitro potency makes it a valuable negative control or case study. It serves as a benchmark compound for demonstrating that high in vitro affinity and selectivity do not guarantee in vivo CNS target engagement, a critical concept in translational neuropharmacology [1]. This property distinguishes it from CNS-active NRIs like reboxetine and atomoxetine.

In vitro NET pharmacology

High-affinity, high-selectivity NET inhibition

Target-engagement assay context; radioligand binding or uptake studies

Neuropathic pain model research

Reported peripheral anti-hyperalgesic response

Endpoint-response review in rodent partial nerve ligation models

Medicinal chemistry SAR

Benzothiophene scaffold potency advantage

Scaffold-hopping and NET affinity optimization studies

Translational PK/PD case study

Documented poor CNS penetration

Negative control for BBB-limited NET inhibitor research

Technical Documentation Hub

Structured technical reading across foundational, methodological, troubleshooting, and validation/comparative pathways. Use the hub when you need more detail before procurement.

38 linked technical documents

Explore Hub

FoundationalNovember 2025

Talsupram: A Technical Guide to its Mechanism of Action as a Selective Norepinephrine Reuptake Inhibitor

FoundationalNovember 2025

A Technical Guide to the Selective Norepinephrine Reuptake Inhibitor Properties of Talsupram

FoundationalNovember 2025

Talsupram: A Technical Guide to its Chemical Structure, Synthesis, and Biological Activity

Quote Request

Request a Quote for Talsupram

Request pricing, availability, packaging, or bulk supply details using the form on the right.

PricingAvailabilityBulk quantity

Response includesPricing, lead time, and availability after review.

Faster handlingAdd destination country, intended use, and packaging preferences when relevant.

Only Quantity, Unit, and Business or Academic Email are required.

Talsupram | 21489-20-3 – ChemicalBook

Talsupram (CAS 21489-20-3) information, including chemical properties, structure, melting point, boiling point, density, formula, …
CAS 21489-20-3 (Talsupram) – BOC Sciences

BOC Sciences is the world-leading provider of special chemicals. We offer qualified product Talsupram (CAS 21489-20-3), please …

Talsupram 21489-20-3 | MedChemExpress

MedChemExpress provides Talsupram CAS 21489-20-3, related Reference Standards, Isotope-Labeled or GMP Grade Compounds, …
Talsupram | 21489-20-3 – ChemicalBook

Visit ChemicalBook To find more Talsupram (21489-20-3) information like chemical properties,Structure,melting point,boiling …
Talsupram|CAS 21400-58-8|DC Chemicals

Talsupram is a selective noradrenaline inhibitor that has a high affinity for the noradrenaline transporter. Talsupram exhibits anti …
Talsupram | 21489-20-3

Visit ChemicalBook To find more Talsupram (21489-20-3) information like chemical properties,Structure,melting point,boiling …
Buy Talsupram (EVT-431337) | 21489-20-3 – evitachem.com

Talsupram is a chemical compound that has gained attention in pharmacological research, particularly in relation to its potential …
Cas 21489-20-3,Talsupram | lookchem

The CAS Registry Mumber 21489-20-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting …
Talsupram | norepinephrine reuptake inhibitor | NRI | CAS#21489-20-3 …

Description: WARNING: This product is for research use only, not for human or veterinary use. Talsupram is a selective …
Talsupram HCl|Selective Norepinephrine Reuptake Inhibitor

Talsupram is a potent, selective NET inhibitor for research. This product is for Research Use Only (RUO). Not for human or …

Reviews

There are no reviews yet.

Be the first to review “Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3”

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

Buy Talsupram (Lu 5-005 or Lu 5-003[1]) Cas 21489-20-3

See also

Talsupram

CAS Number

Product Name

IUPAC Name

Molecular Formula

Molecular Weight

InChI

InChI Key

SMILES

Synonyms

Canonical SMILES

Technical Parameters

Structure & Identifiers

Talsupram (CAS 21489-20-3): A High-Affinity, Selective Norepinephrine Reuptake Inhibitor (NRI) for Neuropharmacology Research

Why Norepinephrine Reuptake Inhibitors (NRIs) Like Talsupram Are Not Interchangeable

Quantitative Evidence for Talsupram Differentiation vs. Closest Analogs

Superior Binding Affinity and Functional Inhibition of NET vs. Closest Structural and Pharmacological Analogs

Enhanced NET Selectivity Profile Over SERT and DAT Compared to Other NRIs

Differentiated Analgesic Efficacy in a Preclinical Model of Neuropathic Pain

Structural Basis for Pharmacological Differentiation: The Benzothiophene Core

CNS Penetration Liability: A Critical Limitation for In Vivo Brain Target Engagement

Defined Research and Industrial Applications for Talsupram Based on Its Specific Profile

Use as a High-Potency, Selective NET Inhibitor for In Vitro and Ex Vivo Pharmacology

A Validated Tool for Probing Noradrenergic Mechanisms in Rodent Models of Neuropathic Pain

Chemical Probe and Scaffold for Medicinal Chemistry SAR Studies

A Cautionary Tale in Translational Pharmacology for CNS Drug Development

Technical Documentation Hub

Talsupram: A Technical Guide to its Mechanism of Action as a Selective Norepinephrine Reuptake Inhibitor

A Technical Guide to the Selective Norepinephrine Reuptake Inhibitor Properties of Talsupram

Talsupram: A Technical Guide to its Chemical Structure, Synthesis, and Biological Activity

Request a Quote for Talsupram

Product Requirements

Contact Details

Additional Details

Reviews

Related products

Buy Deoxyepinephrine (N-methyldopamine) Cas 501-15-5

Buy Ethylnorepinephrine (Etanor) Cas 536-24-3

Buy Guanabenz (Wytensin) Cas 5051-62-7